Invited Speaker

The Number of New Agents in the Pipeline is Scarce
Jordi Rello
Spain

New antimicrobials in development are half of new vaccines. Recent pharmaceutical developments focus on narrow-spectrum antibiotics. Whereas a potential glut of agents against Gram positive Cocci is coming, the number of new agents in front of Gram negative Bacilli, particularly is of concern.

Modification of pharmacokinetic/pharmacodynamic parameters using different dosage or extended infusion, use for alternative routes (nebulization) or “re-discovery” of old agents are recent research alternatives to fill this gap.

Newer strategies to incentive the development of new antimicrobial agents are clearly needed. The use of antimicrobial strategies reinforcing diversity is a useful way to protect the emergence of new resistances.